Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00345930 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DILIN - Prospective Study

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv32
  2. Study sites: 7 to 6v31
  3. Study sites: 6 to 7 Study title expanded, about 1 wordv30 Show 1 more changeShow less
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Primary and study completion dates: Jun 2028 to Jul 31, 2028v29
  5. Primary and study completion dates: Jun 2023 to Jun 2028v28
Show 26 earlier versionsHide 26 earlier versions
  1. Enrollment target: 1600 to 4000v27
  2. Site contacts updated at 2 of 6 sitesv26
  3. Site contacts updated at 4 of 6 sitesv25
  4. Re-verified, no change to tracked fieldsv24
  5. Site contacts updated at 2 of 6 sitesv23
  6. Primary and study completion dates: Jul 2022 to Jun 2023 Site contacts updated at 3 of 6 sitesv22 Show 1 more changeShow less
    • Site contacts updated at 3 of 6 sites
  7. Primary and study completion dates: Jul 2018 to Jul 2022 Site contacts updated at 2 of 6 sitesv21 Show 1 more changeShow less
    • Site contacts updated at 2 of 6 sites
  8. Primary completion date: Jul 2017 to Jul 2018v20
  9. Site contacts updated at 2 of 6 sitesv19
  10. Study description expanded, about 3 wordsv18 See this version in full on ClinicalTrials.gov ↗
  11. Site contacts updated at 1 of 6 sites Study description expanded, about 5 wordsv17 Show 1 more changeShow less
    • Study description expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  12. Enrollment target: 900 to 1600v16
  13. Site contacts updated at 2 of 6 sitesv15
  14. Study sites: 8 to 6v14
  15. Primary completion date: Aug 2013 to Jul 2017 Completion date: Aug 2013 to Jul 2018 · Site contacts updated at 1 of 8 sitesv13 Show 2 more changesShow less
    • Completion date: Aug 2013 to Jul 2018
    • Site contacts updated at 1 of 8 sites
  16. Study sites revised (8)v12 See this version in full on ClinicalTrials.gov ↗
  17. 3 versions Re-verified since Aug 7, 2012, no change to tracked fieldsv9-v11
  18. Site details revised at 2 of 8 sitesv8
  19. Re-verified, no change to tracked fieldsv7
  20. Enrollment target: 450 to 900 Study sites: 5 to 8 · Primary completion date: Aug 2013 · Completion date: Aug 2008 to Aug 2013 · 2 morev6 Show 5 more changesShow less
    • Study sites: 5 to 8
    • Primary completion date: Aug 2013
    • Completion date: Aug 2008 to Aug 2013
    • Publications: 11 to 13
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  21. Enrollment target: 450 Site contacts updated at 2 of 5 sitesv5 Show 1 more changeShow less
    • Site contacts updated at 2 of 5 sites
  22. Completion date: May 2008 to Aug 2008 Site contacts updated at 2 of 5 sitesv4 Show 1 more changeShow less
    • Site contacts updated at 2 of 5 sites
  23. Study description shortened, about 29 wordsv3 See this version in full on ClinicalTrials.gov ↗
  24. Eligibility criteria shortened, about 85 words Study description shortened, about 23 words · Site contacts updated at 1 of 5 sites · Publications: 19 to 11v2 Show 3 more changesShow less
    • Study description shortened, about 23 words
    • Site contacts updated at 1 of 5 sites
    • Publications: 19 to 11

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Duke University
457 trials monitored
See 52 trials at risk
The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.
Trial Details
NCT Number NCT00345930
Lead Sponsor Duke University
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Liver Diseases
Enrollment 4,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov